PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 14, 2026Journal of the Science of Food and Agriculture0 citations

Covalently Crosslinked Chitosan–Astaxanthin Nanoparticles for Chronic Colitis Relief

Covalently crosslinked chitosan–astaxanthin nanoparticles: a stable, bioavailable oral delivery system with potentiated relief efficacy against chronic colitis

View Full Paper
Ask AI
Bookmark
Share

Authors

XGX Z GongHLHui LiLYLu Yang

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved chronic colitis symptoms in mice using chitosan–astaxanthin nanoparticles, suggesting therapeutic potential.

Key Points

  • This study aims to enhance the stability and efficacy of astaxanthin for delivering relief against chronic colitis.
  • Chitosan was covalently crosslinked with astaxanthin to synthesize nanoparticles.
  • The nanoparticles were characterized for size, zeta potential, and encapsulation efficiency.
  • A chronic colitis model was induced in mice using dextran sulfate sodium (DSS) and treated with the nanoparticles.
  • CS–ASTNPs significantly improved mouse body weight (increase by X grams), colon length (increase by Y cm), and DAI scores (dropped by Z points, P<0.05).
  • Pro-inflammatory cytokines (TNF‐α, IL‐1β) were reduced while IL‐10 levels increased, indicating anti-inflammatory effects.
  • Beneficial bacteria richness increased, particularly in Bacteroidetes and Lactobacillus populations.

Cite This Study

Gong et al. (2026) studied this question.

synapsesocial.com/papers/6a55d11a5aafca87247f8281https://doi.org/10.1002/jsfa.70895
View Full Paper
Ask AI
Bookmark
Share